How should we monitor the cardiovascular benefit of sodium–glucose cotransporter 2 inhibition?

Sodium–glucose cotransporter 2 (SGLT2) inhibitors are increasingly prescribed for the treatment of patients with type 2 diabetes to reduce the risk of cardiovascular events, including heart failure (HF). The mechanisms by which SGLT2 inhibitors reduce such risk are likely to be independent of diabet...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Atsushi, Node, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722318/
https://www.ncbi.nlm.nih.gov/pubmed/33287812
http://dx.doi.org/10.1186/s12933-020-01191-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722318/
https://www.ncbi.nlm.nih.gov/pubmed/33287812
http://dx.doi.org/10.1186/s12933-020-01191-5

Ejemplares similares